<div id="readability-page-1"><div>(TheNewswire)<ul><ul></ul></ul> Vancouver, British Columbia – TheNewswire - March 19, 2026 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF), (the “Company” or “MindBio”), a biotechnology company commercializing AI-driven voice analytics for drug and alcohol intoxication detection announces today that it is upsizing its non-brokered private placement (the “Offering”) previously announced on February 18, 2026 from $650,000 to up to $1,500,000, pursuant to which the Company intends to now issue up to 2,500,000 units of the Company (the “Units”) at a price of $0.60 per Unit for gross proceeds of up to $1,500,000. Each Unit will consist of one common share of the Company (each, a “Share”) and one Share purchase warrant (each, a “Warrant”). Each Warrant will entitle the holder to acquire an additional Share at a price of $0.80 for a period of thirty-six months following closing of the Offering, subject to accelerated expiry in the event the closing price of the Shares on the Canadian Securities Exchange exceeds $1.00 for ten consecutive trading days. In connection with completion of the Offering, the Company will pay finders’ fees to eligible third-parties who have introduced subscribers to the Offering. All securities issued in connection with the Offering will be subject to restrictions on resale for a period of four-months-and-one-day in accordance with applicable securities laws. Completion of the Offering remains subject to final board and regulatory approvals. For further information, please contact: Justin Hanka, Chief Executive Officer +61 433140886 justin@mindbiotherapeutics.comwww.mindbiotherapeutics.comAbout MindBio TherapeuticsCorp.MindBio is a biotechnologycompany that is commercialising AI prediction technologies for drugand alcohol intoxication detection via voice analysis. The AIprediction model uses over 50 million data points to predict alcoholintoxication with remarkable accuracy, just by using the human voice.The Company is developing an enterprise platform including Edge-AIkiosks integrating bespoke hardware and software for the detection ofdrug and alcohol intoxication using the human voice and AI in a rangeof enterprise environments including the mining industry, aviation,construction and law enforcement.Cautionary Note ConcerningForward-Looking Statements: The press release contains“forward-looking statements” within the meaning of applicablesecurities laws, including but not limited to, the Company’s abilityto complete the Offering. Forward-looking statements can be identifiedby words such as: “anticipate,” “intend,” “plan,”“budget,” “believe,” “project,” “estimate,”“expect,” “scheduled,” “forecast,” “strategy,”“future,” “likely,” “may,” “to be,” “could,”“would,” “should,” “will” and similar references to futureperiods or the negative or comparable terminology, as well as termsusually used in the future and conditional. Forward-looking statementsare based on assumptions as of the date they are provided. However,there can be no assurance that such assumptions will reflect theactual outcome of such items or factors. Additionally, there are known andunknown risk factors that could cause the Company’s actual resultsand financial conditions to differ materially from those indicated inthe forward-looking statements. Therefore, you should not rely on anyof these forward-looking statements. Important risk factors that couldcause actual results and financial conditions to differ materiallyfrom those indicated in the forward-looking statements, include amongothers: the risk that the Company may not be able to raise the grossproceeds of the Offering; the failure to obtain the final regulatoryapproval; and technical challenges in the development or deployment ofits enterprise platform; general economic, market and business conditions in Canada andAustralia; market volatility; and unforeseen delays in timelines forany of the transactions or events described in this press release. All forward-looking information is qualified in its entirety by thiscautionary statement. The Company disclaims any obligationto revise or update any such forward-looking statement or to publiclyannounce the result of any revisions to any of the forward-lookinginformation contained herein to reflect future results, events ordevelopments, except as required by law.Neither the Canadian SecuritiesExchange nor its Regulation Service Provider (as that term is definedin the policies of the Canadian Securities Exchange) acceptsresponsibility for the adequacy or accuracy of this release.Copyright (c) 2026 TheNewswire - All rights reserved.</div></div>

IBBQ

MindBio Therapeutics Corp. has announced an increase in its non-brokered private placement from $650,000 to up to $1.5 million. The company plans to issue up to 2.5 million units at $0.60 each, with each unit consisting of one common share and one warrant. The warrants allow for the purchase of additional shares at $0.80 for 36 months. The offering is subject to regulatory approvals and will include finders' fees for eligible third parties. All securities will have a four-month resale restriction.

The newswire.ca

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

iShares Biotechnology ETF

SPDR S&P Biotech

VG Health

Proshares UltraShort Nasdaq Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

MindBio Announces Upsize to Private Placement up to $1.5 Million